CAR-T Archives

Blog

2025 Oncology Mid-Year Check-in: Reflections & Expectations

June 20, 2025

Reflecting on the first half of 2025 including data from AACR, ASCO and EHA, we see several notable trends continuing to shape the oncology landscape. While development follows momentum observed the last few years, these learnings provide a clearer understanding into...

Hug with Cancer patient and her daughter

Blog

Key Takeaways and Learnings from ASH 2023

January 12, 2024

Introduction The Trinity Life Sciences’ team recently attended the 65th ASH Annual Meeting and Exposition from December 9-12, 2023, in San Diego, California. The conference brought together physicians, scientists and industry experts to share and collaborate on advances in understanding and...

Blog

Mapping the Unknown: Measuring Cell and Gene Therapy Adoption Using Real-World Evidence

August 9, 2022

It’s been 10 years since the first pediatric patient was treated with chimeric antigen receptor T-cell (CAR-T) therapy for her acute lymphoblastic leukemia. At the time, the approach to engineer immune cells was a novel, ground-breaking concept. In the subsequent decade,...

Blog

Assessing the Value of Non-Curative Cell and Gene Therapies

October 6, 2021

Executive Summary Trinity’s Take: Manufacturers should prioritize refining and tailoring their value messaging to communicate the incremental value that their therapy provides over current treatments, optimize their pricing strategy based on the cost-offsets their product generates, and pursue contracting strategies to...

Blog

CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA

September 22, 2020

Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site...